NasdaqCM:CLDXBiotechs
Assessing Celldex Therapeutics's Valuation After Encouraging Phase 2 Barzolvolimab Results and Renewed Pipeline Optimism
Celldex Therapeutics (CLDX) has attracted attention recently after announcing encouraging results from its Phase 2 trial for barzolvolimab. The therapy showed successful mast cell depletion in eosinophilic esophagitis and delivered positive outcomes for chronic spontaneous urticaria, two areas where new treatment options are in demand. Although the therapy did not yield symptom improvement in eosinophilic esophagitis, the study’s biological results have sparked renewed interest among...